SCHEDULE 13G/A: BlackRock Amends Stake in Cardlytics, Reports 2.1% Passive Ownership

Sentiment:

Beneficial Ownership Report


BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, disclosing a 2.1% passive beneficial ownership stake in Cardlytics, Inc. as of June 30, 2025.

Summary

  • BlackRock, Inc. filed an Amendment No. 6 to Schedule 13G regarding its ownership in CARDLYTICS,INC.
  • BlackRock beneficially owns 1,098,977 shares of Cardlytics Common Stock.
  • This represents 2.1% of the class of securities.
  • BlackRock holds sole voting power over 1,095,873 shares and sole dispositive power over 1,098,977 shares.
  • The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cardlytics.

Sentiment

Score: 5

Explanation: The document is a factual, routine disclosure of passive ownership by an institutional investor, containing no positive or negative operational or financial news about the issuer.

Future Outlook

NA

Management Comments

  • To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a routine disclosure by a large institutional investor, BlackRock, Inc., detailing its passive ownership stake in Cardlytics, Inc. It reflects standard portfolio management activities rather than a strategic industry move or competitive action.

Stakeholder Impact

  • This filing primarily impacts shareholders by providing transparency on a significant institutional holding. It indicates BlackRock's continued passive investment in Cardlytics, which may be viewed as a vote of confidence by some investors, though it does not imply active involvement in company operations or strategy.

Key Dates

DateDescription
2023-04-30Date of previous Power of Attorney revoked by the new one.
2025-01-21Date of the new Power of Attorney for BlackRock, Inc.
2025-06-30Date of event which requires filing of this statement (beneficial ownership calculation date).
2025-07-16Date of filing/signature of the Schedule 13G Amendment No. 6.

Keywords

Cardlytics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Passive Investment, Financial Filing, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.